Curosurf

Curosurf (Poractant Alfa) is a surfactant replacement therapy used to treat respiratory distress in premature infants. This product, manufactured by Chiesi Farmaceutici S.P.A., is designed for endotracheal administration to improve lung function and oxygenation.

Curosurf is primarily used to treat respiratory distress syndrome (RDS) in premature infants. This condition occurs when the lungs do not produce enough surfactant, a substance that keeps the air sacs open. By administering Curosurf, healthcare providers aim to replace the missing surfactant and improve breathing. The therapy is typically used in neonatal intensive care units (NICUs) to support the respiratory health of premature babies.

Curosurf works by coating the inner surface of the lungs, reducing surface tension and preventing the collapse of the air sacs. This helps to improve lung compliance and gas exchange, making it easier for premature infants to breathe. The effects of Curosurf are generally observed shortly after administration, providing immediate relief to infants suffering from respiratory distress.

Curosurf should be administered by trained healthcare professionals in a controlled medical environment. It is crucial to follow proper handling and storage guidelines to maintain the efficacy of the product. Patients with known allergies to any of the components should avoid using Curosurf. Always consult a healthcare provider for personalized advice.

Curosurf is generally used as a standalone therapy, but interactions with other medications should be monitored. It is important to inform healthcare providers about all medications being administered to the infant to avoid potential complications. Always follow the guidance of a healthcare professional when using Curosurf in conjunction with other treatments.